NovaDel Issued Canadian Patent for Oral Spray Delivery of Major Classes of Pharmaceuticals.FLEMINGTON, N.J. -- NovaDel Pharma Inc. (AMEX AMEX See: American Stock Exchange : NVD See National Vulnerability Database. ) today announced the issuance of a patent by the Canadian Patent Office covering the use of multiple classes of drugs in oral sprays. Canadian Patent No. 2,252,050 covers a buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal aerosol spray composition for transmucosal administration of a pharmacologically acceptable non-polar solvent propellant selected from the group consisting of alkaloids alkaloids, n alkaline phytochemicals that contain nitrogen in a heterocyclic ring structure. They can have powerful pharmacological effects and are more often used in traditional medicine than in herbal treatments. , anti-histamines, steroid hormones, non-steroidal anti-inflammatories, analgesics, benzodiazepines Benzodiazepines Definition Benzodiazepines are medicines that help relieve nervousness, tension, and other symptoms by slowing the central nervous system. Purpose Benzodiazepines are a type of antianxiety drugs. and anti-depressants. "This Canadian patent further strengthens NovaDel's intellectual property position in the oral-spray administration of numerous classes of pharmaceuticals," commented Jan Egberts, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of NovaDel. "We believe that the application of NovaDel's technology to approved pharmaceutical compounds may provide significant benefits to patients through ease of use as a well as offer a rapid product development and registration strategy to our Company and its shareholders." NovaDel's patent portfolio includes 143 issued and pending patent applications worldwide. About NovaDel Pharma, Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient the potential for (i) fast onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. ; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. To find out more about NovaDel Pharma Inc. (AMEX: NVD), visit our website at www.novadel.com. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the successful completion of its pilot pharmacokinetic feasibility studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals for products under development and the acceptance in the marketplace for lingual spray products. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion